Zenagamtide

Zenagamtide

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

An investigational peptide formerly called amycretin. Human studies have tested oral and injected forms for weight and type 2 diabetes research. It is not FDA approved.

Plain English

Zenagamtide is one molecule designed to act on several appetite-related hormone receptors. Researchers are testing a pill and an injection. Results from one form or patient group should not be assumed to apply to the other.

Overview

Zenagamtide, formerly amycretin, is an investigational peptide with activity at GLP-1, amylin, and calcitonin receptors. Oral and subcutaneous formulations have been studied in people with overweight or obesity and in people with type 2 diabetes. Neither formulation has an approved U.S. indication.

Research Areas

  • Obesity
  • Type 2 diabetes
  • GLP-1 and amylin research

Safety & Risks

Reported Side Effects

  • Gastrointestinal adverse events
United States
Investigational; not FDA-approved.
United Kingdom
Current authorization status not established in this record.
Australia
Current authorization status not established in this record.
Canada
Current authorization status not established in this record.

Citations & Sources